1. Home
  2. SENS vs TBPH Comparison

SENS vs TBPH Comparison

Compare SENS & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SENS
  • TBPH
  • Stock Information
  • Founded
  • SENS 1996
  • TBPH 2013
  • Country
  • SENS United States
  • TBPH United States
  • Employees
  • SENS N/A
  • TBPH N/A
  • Industry
  • SENS Industrial Machinery/Components
  • TBPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • SENS Industrials
  • TBPH Health Care
  • Exchange
  • SENS Nasdaq
  • TBPH Nasdaq
  • Market Cap
  • SENS 396.0M
  • TBPH 464.5M
  • IPO Year
  • SENS N/A
  • TBPH N/A
  • Fundamental
  • Price
  • SENS $0.52
  • TBPH $9.16
  • Analyst Decision
  • SENS Strong Buy
  • TBPH Buy
  • Analyst Count
  • SENS 2
  • TBPH 3
  • Target Price
  • SENS $2.00
  • TBPH $11.33
  • AVG Volume (30 Days)
  • SENS 6.9M
  • TBPH 285.7K
  • Earning Date
  • SENS 05-08-2025
  • TBPH 05-08-2025
  • Dividend Yield
  • SENS N/A
  • TBPH N/A
  • EPS Growth
  • SENS N/A
  • TBPH N/A
  • EPS
  • SENS N/A
  • TBPH N/A
  • Revenue
  • SENS $23,682,000.00
  • TBPH $65,266,000.00
  • Revenue This Year
  • SENS $60.14
  • TBPH $51.09
  • Revenue Next Year
  • SENS $36.55
  • TBPH N/A
  • P/E Ratio
  • SENS N/A
  • TBPH N/A
  • Revenue Growth
  • SENS 1.64
  • TBPH 6.11
  • 52 Week Low
  • SENS $0.25
  • TBPH $7.44
  • 52 Week High
  • SENS $1.40
  • TBPH $10.90
  • Technical
  • Relative Strength Index (RSI)
  • SENS 39.02
  • TBPH 46.92
  • Support Level
  • SENS $0.52
  • TBPH $9.10
  • Resistance Level
  • SENS $0.54
  • TBPH $9.45
  • Average True Range (ATR)
  • SENS 0.04
  • TBPH 0.36
  • MACD
  • SENS -0.00
  • TBPH -0.02
  • Stochastic Oscillator
  • SENS 16.29
  • TBPH 65.35

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: